Curevac | Pandemic PACT Tracker

Key facts

Disease
COVID-19
Known Financial Commitments (USD)
$15,300,000
Funder
Coalition for Epidemic Preparedness Innovations (CEPI)
Principal Investigator
N/A
Research Location
Germany
Lead Research Institution
Curevac
Research Priority Alignment
N/A

Research Category
Vaccines research, development and implementation
Research Subcategory
Phase 1 clinical trial
Special Interest Tags
N/A
Study Type
Clinical
Clinical Trial Details
Clinical Trial, Phase I
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified

Abstract

mRNA Full Length S stabilized (unmodified and codon optimized) Phase I safety and immunogenicity

Publicationslinked via Europe PMC

Last Updated:5 days ago

View all publications at Europe PMC

Acceptability of digital health intervention during pregnancy to inform women about postpartum contraception (DIGICAP): a pilot randomised controlled study.

Feasibility of a ctDNA multigenic panel for non-small-cell lung cancer early detection and disease surveillance.

A framework for safe, healthy and sustainable participation in elite Para sport.

Phycobilisome core architecture influences photoprotective quenching by the Orange Carotenoid Protein.

A molecular probe for detecting cholinesterase activity in MRI.

Visual context affects the perceived timing of tactile sensations elicited through intra-cortical microstimulation: a case study of two participants.

Considerations for a women's rehabilitation programme following anterior cruciate ligament reconstruction: a concept mapping approach to enhance women's outcomes.

Longitudinal idiographic assessment of adolescent-dog relationships and adaptive coping for youth with social anxiety: The Teen & Dog Study protocol.

Sepsis-related myocardial injury: the role of bacterial pathogens and toxins-a scoping review protocol.